

CORRECTED VERSION

(19) World Intellectual Property
Organization
International Bureau



WIPO | PCT



(10) International Publication Number
WO 2012/020848 A8

(43) International Publication Date
16 February 2012 (16.02.2012)


- (51) International Patent Classification:
C07D 513/04 (2006.01) *A61P 25/00* (2006.01)
A61K 31/542 (2006.01)
- (21) International Application Number:
PCT/JP2011/068497
- (22) International Filing Date:
9 August 2011 (09.08.2011)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
2010-179577 10 August 2010 (10.08.2010) JP
- (71) Applicant (for all designated States except US): **TAKEDA PHARMACEUTICAL COMPANY LIMITED** [JP/JP]; 1-1, Doshomachi 4-chome, Chuo-ku, Osaka-shi, Osaka, 5410045 (JP).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **KORI, Masakuni** [JP/JP]; c/o TAKEDA PHARMACEUTICAL COMPANY LIMITED, 17-85, Jusohonmachi 2-chome, Yodogawa-ku, Osaka-shi, Osaka, 5320024 (JP). **IMAEDA, Toshihiro** [JP/JP]; c/o TAKEDA PHARMACEUTICAL COMPANY LIMITED, 17-85, Jusohonmachi 2-chome, Yodogawa-ku, Osaka-shi, Osaka, 5320024 (JP). **NAKAMURA, Shinji** [JP/JP]; c/o TAKEDA PHARMACEUTICAL COMPANY LIMITED, 26-1, Muraokahigashi 2-chome, Fujisawa-shi, Kanagawa, 2510012 (JP). **TOYOFUKU, Masashi** [JP/JP]; c/o TAKEDA PHARMACEUTICAL COMPANY LIMITED, 26-1, Muraokahigashi 2-chome, Fujisawa-shi,

Kanagawa, 2510012 (JP). **HONDA, Eiji** [JP/JP]; c/o TAKEDA PHARMACEUTICAL COMPANY LIMITED, 26-1, Muraokahigashi 2-chome, Fujisawa-shi, Kanagawa, 2510012 (JP). **ASANO, Yasutomi** [JP/JP]; c/o TAKEDA PHARMACEUTICAL COMPANY LIMITED, 26-1, Muraokahigashi 2-chome, Fujisawa-shi, Kanagawa, 2510012 (JP). **UJIKAWA, Osamu** [JP/JP]; c/o TAKEDA PHARMACEUTICAL COMPANY LIMITED, 17-85, Jusohonmachi 2-chome, Yodogawa-ku, Osaka-shi, Osaka, 5320024 (JP). **MOCHIZUKI, Michiyo** [JP/JP]; c/o TAKEDA PHARMACEUTICAL COMPANY LIMITED, 26-1, Muraokahigashi 2-chome, Fujisawa-shi, Kanagawa, 2510012 (JP).

- (74) Agent: **TAKASHIMA, Hajime**; Meiji Yasuda Seimei Osaka Midouji Bldg., 1-1, Fushimimachi 4-chome, Chuo-ku, Osaka-shi, Osaka, 5410044 (JP).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG,

[Continued on next page]

(54) Title: HETEROCYCLIC COMPOUND AND USE THEREOF



(57) Abstract: Provided is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA (α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.



ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

— with sequence listing part of description (Rule 5.2(a))

(48) Date of publication of this corrected version:

27 September 2012

(15) Information about Correction:

see Notice of 27 September 2012

Published:

— with international search report (Art. 21(3))